



This is an official CDC HEALTH ADVISORY



Risk of Severe Arboviral Disease in Patients Receiving B Cell-Depleting or Modulating Medications

[LINK TO FULL REPORT](#)

CS-356453

August 11, 2026

CDCHAN-00532

Summary

The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory to share information and notify clinicians, public health authorities, and the public about the risk of severe arboviral neuroinvasive disease among patients who are receiving B cell-depleting or B cell-modulating medications, particularly anti-CD20 monoclonal antibodies (mAbs). Patients and their providers should be aware of this risk to help patients [protect themselves against the bites of mosquitoes and ticks](#), which can increase patients' risk of arboviral disease.

View the [full report](#).

South Dakota Summary

West Nile virus (WNV) is the primary arboviral disease concern in South Dakota. So far in 2026, five WNV cases have been reported to the South Dakota Department of Health (SD-DOH), including two neuroinvasive disease cases. WNV surveillance data are available on the [SD-DOH WNV Dashboard](#) (last updated August 5, 2026). Healthcare providers evaluating patients with suspected arboviral disease, including WNV, should collect appropriate specimens for testing. Arboviral disease cases, neuroinvasive and non-neuroinvasive, should be reported to SD-DOH within three days (Category II disease). Reports can be submitted at sd.gov/diseasereport.